U.S. Food and Staples Retail Stock News

NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

Is It Too Late To Consider EyePoint (EYPT) After A 133% One-Year Surge?

Wondering whether EyePoint at US$13.66 still offers value after a big run, or whether most of the opportunity is already priced in. The stock is up 133.5% over the past year and 127.7% over three years, even though it has fallen 1.4% over the last week, 3.7% over the past month and 21.9% year to date. Recent market attention on EyePoint has focused on its position within the US pharmaceuticals and biotech space and how investors are reassessing risk across smaller healthcare stocks...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?

If you are wondering whether Amylyx Pharmaceuticals at US$14.73 is still offering value after a strong run, it helps to step back and look at what the price is really reflecting. The stock is up 29.0% year to date and 220.2% over the past year, even though it has fallen about 10.5% over the past week and 10.0% over the past month. These moves can change how you think about both opportunity and risk. Across financial media and industry commentary, recent attention has focused on Amylyx as a...
NYSE:BBU
NYSE:BBUIndustrials

A Look At Brookfield Business Partners (NYSE:BBU) Valuation After Softer Q1 Earnings And Recent Share Price Pullback

Q1 earnings and dividend decision put Brookfield Business Partners (NYSE:BBU) in focus Brookfield Business Partners (NYSE:BBU) is drawing attention after Brookfield Business Corporation reported first quarter 2026 results with lower sales and net income, alongside a fresh quarterly dividend declaration. For the quarter ended March 31, 2026, Brookfield Business Corporation reported sales of US$6,436 million, compared with US$6,749 million a year earlier, and net income of US$40 million,...